Abstract
OBJECTIVES: The Node Reporting and Data System (Node-RADS) offers a reliable framework for lymph node assessment, but its prognostic significance remains unexplored. This study aims to investigate the added prognostic value of Node-RADS in patients with locally advanced gastric cancer (LAGC) undergoing neoadjuvant chemotherapy (NAC) followed by gastrectomy. MATERIALS AND METHODS: This single-center retrospective study included 118 patients with LAGC underwent NAC and gastrectomy. The maximum Node-RADS score and the number of metastatic lymph node stations (defined as LNM-Station) were evaluated on pretreatment CT. The pretreatment Node-RADS-CT and Node-RADS-integrated models were developed using Cox regression to predict overall survival (OS) and disease-free survival (DFS). The pretreatment cN-CT models, cN-integrated models, as well as post-NAC pathological models were also developed in comparison. The performance of the models was assessed in terms of discrimination, calibration and clinical applicability. RESULTS: The LNM-Station was significantly associated with OS and DFS (all p < 0.05). The Node-RADS-CT model showed higher Harrell's consistency index (C-index) than cN-CT model (0.755 vs. 0.693 for OS, p = 0.017; 0.759 vs. 0.706 for DFS, p = 0.018). The Node-RADS-integrated model also achieved higher C-index than cN-integrated model (0.771 vs. 0.731 for OS, p = 0.091; 0.773 vs. 0.733 for DFS, p = 0.053). The net reclassification improvement (NRI) of the Node-RADS-integrated model at 5 years was 0.379 for OS and 0.364 for DFS (all p < 0.05). The integrated discrimination improvement (IDI) of the Node-RADS-integrated model was 0.103 for OS and 0.107 for DFS (all p < 0.05). The C-indices (OS: 0.745; DFS: 0.746) of pathological models were slightly lower than those of Node-RADS-based models (all p > 0.05). CONCLUSION: The baseline Node-RADS score and LNM-Station were effective prognostic indicators for LAGC. The pretreatment CT Node-RADS-based models can offer added prognostic value for LAGC, compared with clinical N stage.